These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25115638)

  • 1. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
    Manfredi GI; Dicitore A; Gaudenzi G; Caraglia M; Persani L; Vitale G
    Endocrine; 2015 Mar; 48(2):363-70. PubMed ID: 25115638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
    Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
    Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
    Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
    Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
    Narayanankutty A
    Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
    Cidado J; Park BH
    J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):205-16. PubMed ID: 22865098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
    Cho DC
    BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
    Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
    Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW; Mariani GL
    Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
    Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
    Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3K/AKT/mTOR network for treatment of leukemia.
    Bertacchini J; Heidari N; Mediani L; Capitani S; Shahjahani M; Ahmadzadeh A; Saki N
    Cell Mol Life Sci; 2015 Jun; 72(12):2337-47. PubMed ID: 25712020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.